Post-COVID-19 Encephalitis in Patient with De Novo Mutation in the SCN1A Gene: A Case Report
March 2022
in “
Piretc
”
TLDR A person with a new mutation in the SCN1A gene developed brain inflammation after COVID-19.
Related Community Posts Join
6 / 1000+ resultscommunity A Summary of the Latest Research regarding PFS, and How Supplementing Allopregnanolone Might Protect Against It
in Chat 5 upvotes 2 years ago Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.
community PP405 (Non) Update - Feb 2025
in Research/Science 34 upvotes 1 year ago The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
community How much would a high dose dutasteride scalp dht inhibition be?
in Finasteride/Dutasteride 10 upvotes 1 year ago The conversation discusses the potential for high doses of dutasteride to completely inhibit scalp DHT and speculates whether this could cure baldness when combined with a topical antiandrogen. Specific dosages mentioned are 0.5 mg reducing scalp DHT by 55% and 2.5 mg by about 79%.
community So we have 20k dollars human like machines available but no new effective treatment for hairloss since finasteride :)
in Chat 237 upvotes 1 year ago There have been no new effective hair loss treatments since finasteride, despite technological advancements. Current treatments include finasteride, minoxidil, and RU58841, with ongoing challenges and potential future solutions in research.
community If PP405 works it will be fkn impossible to buy it.
in Technology 100 upvotes 4 months ago PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.
community I have heard that Amplifica - Scube3 initiate a human study for AGA, but I cannot find any information about it from clinictrial.gov. Amplifica did not state it is a phase 1 clinic trial or not, it says it is "The initiation of our first-in-human clinical study"
in Technology 2 upvotes 2 years ago The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
Related Research
1 / 1 results
research Post-COVID-19 Encephalitis in Patient with De Novo Mutation in the SCN1A Gene: A Case Report
March 2022 in “Piretc” A person with a new mutation in the SCN1A gene developed brain inflammation after COVID-19.